Longeveron ELPIS II misses HLHS primary endpoint; strategic review starts
Longeveron said its ELPIS II trial in HLHS did not meet the primary RVEF endpoint (LS mean diff −0.7 pts; p=0.8336) and has begun a review of options to maximize shareholder value, including cash conservation. Safety was generally consistent with prior studies.
8336. The company also said it has started a review of all options to maximize shareholder value, including cash conservation. Safety was generally consistent with prior studies.